N-acetylglutamic acid-N-(N(2)-(5-n-butyl-2-pyridyl)hydrazide): renal vasodilator agent with natriuretic properties; RN refers to NH3 salt; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 125985 |
| MeSH ID | M0130539 |
| Synonym |
|---|
| cgp 22979a |
| 96558-25-7 |
| n-acetylglutamic acid-n-(n(2)-(5-n-butyl-2-pyridyl)hydrazide) |
| cgp-22979-a |
| cgp-22979a |
| l-glutamic acid, n-acetyl-, 5-(2-(5-butyl-2-pyridinyl)hydrazide), monoammonium salt |
| 5-[2-(5-butylpyridin-2-yl)hydrazinylidene]-5-hydroxy-n-(1-hydroxyethylidene)norvaline--ammonia (1/1) |
| DTXSID90914460 |
| (2s)-2-acetamido-5-[2-(5-butylpyridin-2-yl)hydrazinyl]-5-oxopentanoic acid;azane |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||